资讯
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...
A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.
The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.
2 天
Clinical Trials Arena on MSNSeismic Therapeutic doses healthy subject cohort in Phase I trial of S-4321Seismic Therapeutic has dosed the first healthy participant cohort in the randomised Phase I trial of bifunctional antibody S ...
VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...
Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount ...
Aspire Biopharma (ASBP) has begun initial production of its single dose pre workout supplement utilizing Aspire’s patent-pending and ...
Perspective, Therapeutics announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of 212PbVMT01, ...
A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...
3 天
Clinical Trials Arena on MSNFirst subject dosed in Amylyx’s Phase I trial of ALS therapyThe trial will explore the ALS biomarkers, including the change from baseline in levels of neurofilament light chain.
The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果